

III Congresso Nacional Ciências Biomédicas Laboratoriais


MUTAÇÕES SINÓNIMAS NA PATOGENESE

Ana Ramos Coelho, Ph.D.


¹ Escola Superior de Tecnologia da Saúde de Lisboa, ESTeSL, Instituto Politécnico de Lisboa, Av. D. João II, Lote 4.69.01, 1990-096 Lisboa, Portugal, ana.ramos@estesl.ipl.pt

² H&TRC - Centro de Investigação em Saúde e Tecnologia




26 outubro 2019



Mutação sinónima vs silenciosa




Contribuição mutações sinónimas cancro



Supek, F., et. al Cell (2014)

Contribuição mutações sinónimas cancro


- Mutações sinónimas constituem 6-8% das mutações driver



- Ganho de *exonic splicing enhancer* (ESE)
- Perda de *exonic splicing silencer* (ESS)

Supek, F., et. al Cell (2014)



Alterações splicing



Cerca de metade mutações sinónimas driver alteram o *splicing*

Supek, F., et. al Cell (2014)


Alterações expressão



- Elevada frequência de mutações 3'UTR presentes em oncogenes sensíveis à dose (sobre-expressão)


Supek, F., et. al Cell (2014)

TP53



Mutações sinónimas resultam em inativação de locais de *splicing*


Supek, F., et. al Cell (2014)





Candeias MM and Marques-Ramos A (unpublished data)




A







B




C






Candeias MM and Marques-Ramos A (unpublished data)




Candeias MM Embo Reports (2016)

NF1




Anastasaki C et al. *Neurol Genet.* (2017)







E Ars et al. *J Med Genet* (2003)

NF1



c.288+1137C>T



Svaasand et al. Hereditary Genet (2015)

Deep-intronic mutations



Mutation	mRNA effect	Protein	LOVD NF1 ID	Ref
c.60+9032_60+9036del5	r.60_61ins60+8962_60+9030	p.Gln20_Leu21ins23	_01129	[22]
c.61-7486G>T	r.60-61ins61-7565_61-7492	p.Gln20_Leu21insThr*	_01132	[22]
c.288+2025T>G	r.288_289ins288+1917_288+2024	p.Gln97*	ND	[23]
c.288+1137C>T	r.288_289ins288+1018_288+1135	p. Gln97Serfs*49	ND	This study
c.888+651T>A §	r. 888_889ins888+653_888+784ins	p.Lys297_Val2818delinsGluLysTyrSer*	ND	[20]
c.888+789A>G	r.888_889ins888+710_888+784	p.Lys297fs	_01154	[22]
c.888+10312A>G	r.888_889ins888+10233_888+10311	p.Lys297fs	_01155	[22]
c.889-942G>T	r.888_889ins889-931_889-873	p.Lys297Valfs*11	ND	[23]
c.1062+113A>G	r.1062_1063ins113	p.Asn355fs	_01620	Italy: Milano
c.1260+1604A>G	r.1260_1261ins1260+1605_1260+1646	p.Asn420_Ser421insLeuThrThr*	_00035	[22,24]
c.1393-592A>G	r.1392_1393ins1393-671_1393-596	p.Ser465Alafs*9	_01179	[22,23]
c.1527+1159C>T	r.1527_1528ins1527+1103_1527+1157	p.Asn510Aspfs*8	ND	[16,23,27]
c.1642-449A>G	Not described	Not described	ND	[28]
c.1721+542A>G	r.1721_1722ins1721+362_1721+537	p.Ser574_Ser575insPhePhe GluLeu*	_01186	[22]
c.3198-314G>A	r.3197-3198ins3198-214-3198-312, sr.3197-3198ins3198-245-3198-312 #	p.Asp1067TrpfsX7	ND	[29]
c.4110+945A>G	r.4110_4111ins105	p.Gln1370_Val1371ins35*27	ND	[25]
c.4173+278A>G α	r.4173_4174ins4173+279_4173+358	p.Val1392Ilefs*9	ND	[26]
c.5749+332A>G	r.5749_5750ins5749+155_5749+331	p.Ser1917Argfs*12	_01315	[16,22,30,33,this study]
c.5750-279A>G	r.5749_5750ins5750_278_5750-108	p.Ser1917delins58	ND	[31,32]
c.7908-321C>G	r.7907_7908ins7908-322_7908-391	p.His2637SerfsX2	ND	[4,23]

Svaasand et al. Hereditary Genet (2015)

Deep-intronic mutations

Disease (OMIM)	Gene	Deep intronic variant	Disease (OMIM)	Gene	Deep intronic variant
Monogenic diseases			Gitelman's Syndrome (263800)		
β-Thalassemia7 (6713985)	<i>HBB</i>	IVS2+705T>G		<i>SLC12A3</i>	c.1670-191C>T c.2548+253C>T
Gyrate atrophy of choroid and retina with or without ornithinemia (258870)	<i>OAT</i>	IVS3+303C>G	Megalencephalic leukoencephalopathy with subcortical cysts (604004)	<i>MLC1</i>	c.895-226T>G
Cystic Fibrosis (2197700)	<i>CFTR</i>	3849+10KbC>T	Retinitis pigmentosa (300424)	<i>OFD1</i>	IVS9+706A>G
			Coffin-Lowry syndrome (303600)	<i>RPS6KA3</i>	c.1228-279T>G
Mucopolysaccharidosis II (309900)	<i>IDS</i>	1131-133A>G	Hyperinsulinemic hypoglycemia, familial, 1 (256450)	<i>ABCC8</i>	c.1333-1013A>G
Hyperphenylalaninemia, BH4-deficient, C (261630)	<i>QDPR</i>	IVS3+2552A>G	Inherited growth-hormone insensitivity (604271)	<i>GHR</i>	c.618+792A>G
Maple syrup urine disease, type II (248600)	<i>DBT</i>	IVS8-550A>G	Hemophilia A (306700)	<i>F8</i>	c.5998+530C>T
Mucopolysaccharidosis type VII (253220)	<i>GUSB</i>	IVS8+0.6kbpdelTC			
Tuberous sclerosis (613254)	<i>TSC2</i>	IVS8+281C>T	Stargardt disease 1 (248200)	<i>ABCA4</i>	c.5196+1056A>G
Congenital cataracts facial dysmorphism neuropathy syndrome (604168)	<i>CTDPI1</i>	IVS6+389C>T	Marfan syndrome (154700)	<i>FBN1</i>	c.6872-961A>G
Central core disease (117000)	<i>RYR1</i>	IVS100+2990A>G	Gorlin syndrome (109400)	<i>PTCHI</i>	c.2561-2057A>G
Hyper IgM Syndrome, type 1 (308230)	<i>CD40L</i>	IVS3-915A>T	Menkes disease (309400)	<i>ATP7A</i>	c.2406+1117A>G
Chronic granulomatous disease (306400)	<i>CYBB</i>	IVS6-1157A>G	Miyoshi muscular dystrophy 1(254130)	<i>DYSF</i>	c.4886+1249G>T
Leber congenital amaurosis 10 (611755)	<i>CEP290</i>	c.2991+1655A>G	Hyperinsulinemic hypoglycemia, familial, 4 (609975)	<i>HADH</i>	c.636+471G>T
Schwartz-Jampel Syndrome (255800)	<i>HSPG2</i>	c.574+481C>T	Ocular albinism (300500)	<i>GPR143</i>	c.659-131T>G
Congenital disorder of glycosylation, type Ia (212065)	<i>PMM2</i>	c.639-15479C>T	Ushar syndrome type II (276901)	<i>USH2A</i>	c.9959-4159A>G c.5573-834A>G c.8845+628C>T
Afibrinogenemia (202400)	<i>FGG</i>	IVS6-320A>T			
Methylmalonic aciduria, mut(0) type (251000)	<i>MUT</i>	IVS11+3691C>A	Complete androgen insensitivity syndrome (300068)	<i>AR</i>	c.2450-118A>G
Propionicacidemia (606054)	<i>PCCB</i>	IVS6+462A>G	Duchenne muscular dystrophy (310200)	<i>DMD</i>	deletion 18 bp ^a
Leigh syndrome (256000)	<i>NDUFS7</i>	c.17-1167C>G	Hereditary tumor syndromes		
Mitochondrial trifunctional protein deficiency (609105)	<i>HADHB</i>	IVS7+614A>G	Retinoblastoma (180200)	<i>RB1</i>	IVS23-1398A>G
Deafness, autosomal dominant 22 (606346)	<i>MYO6</i>	IVS23+2321T>G	Lynch syndrome (120435)	<i>MSH2</i>	c.212-478T>G
Polycystic kidney and hepatic disease (263200)	<i>PKHD1</i>	IVS46+1653A>G	Breast cancer (114480)	<i>BRCA2</i>	c.6937+594T>G
Amyotrophic lateral sclerosis 1 (105400)	<i>SOD1</i>	c.358-304C>G	Familial Adenomatous Polyposis (175100)	<i>APC</i>	c.532-941G>A c.1408+731C>T c.1408+735A>T
Niemann-Pick disease, type C1 (250227)	<i>NPC1</i>	c.1554-1009G>A			
Retinitis pigmentosa 11 (600138)	<i>PRPF31</i>	c.1374+654C>G	Neurofibromatosis type 2 (101000)	<i>NF2</i>	c.1447-240T>A
Duchenne muscular dystrophy (310200)	<i>DMD</i>	c.3787-843C>A c.9807+2714C>T	Neurofibromatosis type 1 (162200)	<i>NF1</i>	c.288+1137C>T
Becker muscular dystrophy (30376)	<i>DMD</i>	c.9225-285A>G	Ataxia-telangiectasia (208900)	<i>ATM</i>	IVS28-159A>G ^a
5-fluorouracil toxicity (274270)	<i>DPYD</i>	c.1129-5923C>G			

Deep-intronic mutations

Disease (OMIM)	Gene	Deep intronic variant
Monogenic diseases		
Alport Syndrome (301050)	<i>COL4A3</i>	
	<i>COL4A5</i>	IVS29+2733A>G
Choroideremia (303100)	<i>CHM</i>	314+10127T>A
Ornithine transcarbamylase deficiency (311250)	<i>OTC</i>	c.540+265G>A
Myopathy with lactic acidosis, hereditary (255125)	<i>ISCU</i>	IVS5+382G>C
Duchenne muscular dystrophy (310200)	<i>DMD</i>	c.5326-215T>G
Becker muscular dystrophy (30376)	<i>DMD</i>	c.93+5590T>A
Werner syndrome (277700)	<i>WRN</i>	c.3234-160A>G
Lesch–Nyhan syndrome (300322)	<i>HPRT</i>	g.36221T>A c.5998+941G>A
Limb-girdle muscular dystrophy type 2A (253600)	<i>CAPN3</i>	c.1782+1072G>C
Optic atrophy plus syndrome (125250)	<i>OPA1</i>	c.610+360G>A c.610+364G>A
Kindler syndrome (173650)	<i>FERMT1</i>	c.1139+740G>A
Pompe disease (232300)	<i>GAA</i>	c.2190-345A>G

Disease (OMIM)	Gene	Deep intronic variant
ESE creation		
Monogenic diseases		
Alport Syndrome (301050)	<i>COL4A5</i>	IVS6+1873G>A
Propionicacidemia (606054)	<i>PCCA</i>	IVS14-1416A>G
Afibrinogenemia (202400)	<i>FGB</i>	c.115-600A>G
Homocystinuria, type cbIE (236270)	<i>MTRR</i>	c.903+469T>C
Becker muscular dystrophy (300376)	<i>DMD</i>	c.3603+2053G>C
Complete androgen insensitivity syndrome (300068)	<i>AR</i>	c.2450-118A>G
ESS disruption		
Monogenic diseases		
Cystic Fibrosis (219700)	<i>CFTR</i>	c.1002–1110_1113delT
Fabry disease (301500)	<i>GLA</i>	c.639+919G>A
Hereditary tumor syndrome		
Ataxia-telangiectasia (208900)	<i>ATM</i>	IVS20-579_IVS20-576

Vaz-Drago et al. Human Genet (2017)

Detecção de mutações

	DNA chip	Target-Seq	Exome	RNA-Seq	WGS
Coding SNV		△	○	△	○
Coding indels		△	○	△	○
Splicing alteration			△	○	○
Promoter mutation					○
Regulatory regions					○
Copy-number alteration	○		△		○
Structural variant				△ (fusion)	○
Pathogen				○	○
Mitochondria			△	△	○
Mutational signature			△		○
Neo-antigen/HLA			○	○	○
Sequence (Gb)	—	0.5-1	10	5-10	90-150
Assay cost (\$)	100	200-500	500	500	1000

SNV, single nucleotide variants; WGS, whole genome sequencing.

Nakagawa H. and Fujita M., Cancer Science (2018)

III Congresso Nacional Ciências Biomédicas Laboratoriais

MUTAÇÕES SINÓNIMAS NA PATOGENESE

Ana Ramos Coelho, Ph.D.

¹ Escola Superior de Tecnologia da Saúde de Lisboa, ESTeSL, Instituto Politécnico de Lisboa, Av. D. João II, Lote 4.69.01, 1990-096 Lisboa, Portugal, ana.ramos@estesi.ipl.pt

² H&TRC - Centro de Investigação em Saúde e Tecnologia

26 outubro 2019